LTR Pharma Ltd (ASX:LTP) Completes A$10.5 million Placement to Expedite Commercialisation of SPONTAN
By API User
Sydney, Australia – 24 July 2024 – LTR Pharma Limited (ASX: LTP) (“LTR Pharma” or “the Company”), a company focused on improving men’s health through the clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction (“ED”) called SPONTAN®, is pleased to announce the successful completion of a A$10.5 million share placement … Continued